1800-272-662
Shopping Cart 0
countryflagAU
Login

Kelyniam Global Inc

Healthcare US KLYG

0.09USD
-(-%)

Last update at 2026-03-12T20:00:00Z

Day Range

0.090.09
LowHigh

52 Week Range

0.060.13
LowHigh

Fundamentals

  • Previous Close 0.09
  • Market Cap4.10M
  • Volume800
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.31004M
  • Revenue TTM2.56M
  • Revenue Per Share TTM0.09
  • Gross Profit TTM 2.37M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax - - - - -0.03360M
Minority interest - - - - 0.00000M
Net income - - - - -0.01530M
Selling general administrative - - - - 1.00M
Selling and marketing expenses - - - - -
Gross profit - - - - 1.06M
Reconciled depreciation - - - - -
Ebit -0.03063M 0.23M 0.08M -0.09423M -0.00757M
Ebitda - - - - -
Depreciation and amortization - - - - -
Non operating income net other - - - - 0.00000M
Operating income - - - - -0.00757M
Other operating expenses 0.05M 0.05M 0.06M 0.05M 0.05M
Interest expense - 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -0.02700M 0.03M 0.02M -0.07795M -0.01830M
Total revenue - - - - 2.12M
Total operating expenses - - - - 2.13M
Cost of revenue - - - - 1.06M
Total other income expense net - - - - -0.02603M
Discontinued operations - - - - 0.00000M
Net income from continuing ops - - - - -0.01530M
Net income applicable to common shares -0.09756M 0.20M 0.14M -0.35795M -0.01530M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets - - - - 1.25M
Intangible assets - - - - 0.02M
Earning assets - - - - -
Other current assets - - - - 0.00000M
Total liab - - - - 0.65M
Total stockholder equity - - - - 0.60M
Deferred long term liab - - - - 0.00000M
Other current liab 0.04M 0.15M - - 0.00000M
Common stock 0.03M 0.03M 0.14M 0.03M 0.02M
Capital stock - - - - -
Retained earnings -2.06037M -1.96281M -2.16455M -2.30562M -1.94767M
Other liab - - - - 0.00000M
Good will - - - - 0.00000M
Other assets 0.47M 0.44M 0.47M 0.49M 0.41M
Cash - - - - 0.05M
Cash and equivalents - - - - -
Total current liabilities 0.69M 0.69M 0.68M 0.88M 0.43M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - 0.00000M
Short long term debt - - - - 0.07M
Short long term debt total - - - - -
Other stockholder equity - - 0.03M 0.00118M 0.00676M
Property plant equipment 0.58M 0.40M 0.43M 0.41M 0.41M
Total current assets 0.66M 0.59M 0.41M 0.62M 0.41M
Long term investments - - - - 0.00000M
Net tangible assets 0.76M 0.69M 0.48M 0.27M 0.58M
Short term investments - - - - 0.02M
Net receivables 0.50M 0.54M 0.27M 0.47M 0.28M
Long term debt - - - - 0.22M
Inventory 0.06M 0.04M 0.08M 0.05M 0.05M
Accounts payable 0.25M 0.11M 0.20M 0.24M 0.16M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - - 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other - - - - 0.00000M
Deferred long term asset charges - - - - 0.00000M
Non current assets total - - - - 0.00000M
Capital lease obligations - - - - 0.00000M
Long term debt total - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - - 0.00347M 0.04M
Change to liabilities 0.00071M 0.09M -0.02623M 0.00069M 0.12M
Total cashflows from investing activities -0.05170M -0.01064M -0.04859M -0.00536M -0.05727M
Net borrowings 0.08M -0.13026M -0.15597M 0.25M -0.05762M
Total cash from financing activities 0.08M -0.13026M -0.23597M 0.28M -0.05762M
Change to operating activities -0.17422M -0.06476M -0.09856M 0.27M -0.15235M
Net income -0.09756M 0.20M 0.14M -0.35795M -0.01530M
Change in cash - - -0.08253M 0.04M -0.09989M
Begin period cash flow - - - - -
End period cash flow - - - - -
Total cash from operating activities -0.03175M 0.14M 0.20M -0.23929M 0.02M
Issuance of capital stock - - - - -
Depreciation 0.05M 0.04M 0.02M 0.02M 0.02M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - 0.00000M
Change to inventory -0.01241M 0.04M -0.03551M 0.00343M -0.01620M
Change to account receivables 0.04M -0.26415M 0.20M -0.19063M 0.08M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities - - - - 0.00000M
Change to netincome 0.17M 0.09M 0.09M 0.02M 0.02M
Capital expenditures 0.05M 0.01M 0.05M 0.00883M 0.10M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital - - - - -
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow - - - - -

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
KLYG
Kelyniam Global Inc		 - -% 0.09 - - 1.60 - 75.85 -9.4777
ABT
Abbott Laboratories		 -0.11 0.10% 108.03 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -0.44 0.13% 336.77 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.24 0.27% 87.14 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.58 0.85% 69.13 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Kelyniam Global, Inc. engages in the production of custom prosthetics cranial implants utilizing computer aided design, and computer aided manufacturing of advanced medical grade polymers in the United States. The company also develops, manufactures, and distributes custom cranial and maxilla-facial implant for patients requiring the reconstruction of cranial and facial structures. It serves surgeons, health systems, and payors. The company was formerly known as Ketner Global Investments, Inc. and changed its name to Kelyniam Global, Inc. in December 2007. Kelyniam Global, Inc. was incorporated in 2005 and is based in Collinsville, Connecticut.

Kelyniam Global Inc

97 River Road, Collinsville, CT, United States, 06019

Key Executives

Name Title Year Born
Mr. Ross Bjella Chairman & CEO 1962
Mr. Terrance Kurtenbach Chief Financial Officer NA
Michael Hamblett Director of Investor Relations NA
Mr. James Barrow Esq. Gen. Counsel and Director of Quality & Regulatory NA
Dr. Mark V. Smith M.D. VP of Sales & Bus. Devel. and Director NA
Dr. Christopher Mirucki Chief Medical Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.